Managing chronic myeloid leukemia: A coordinated team care perspective

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 2, 2012, Pages 88-93

  Holloway, Stacie ^a   Lord, Katharine ^a   Bethelmie Bryan, Beverly ^b   Shepard, Marian W ^b   Neely, Jessica ^b   McLemore, Morgan ^b   Reddy, Satyanarayan K ^c   Montero, Aldemar ^d   Jonas, William S ^e   Gladney, Sara Pierson ^e   Khanwani, Shyam L ^f   Reddy, Silpa C ^g   Lahiry, Anup K ^h   Heffner, Leonard T ^b   Winton, Elliott ^b   Arellano, Martha ^b   Khoury, Hanna Jean ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c South Atlanta Hematology Oncology   (United States)

^d Suburban Hematology Oncology Associates   (United States)

^e Atlanta Hematology and Oncology Associates   (United States)

^f Georgia Cancer Specialists   (United States)

^g Atlanta Cancer Care   (United States)

^h Longstreet Cancer Center   (United States)

Author keywords

Adherence; BCR ABL; Multidisciplinary team; Patient education; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ANEMIA; ARTHRALGIA; ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; COORDINATION; CYTOGENETICS; DISEASE COURSE; DIZZINESS; EDUCATIONAL STATUS; EPIGASTRIC PAIN; FAINTNESS; FLUID RETENTION; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEADACHE; HEALTH SERVICE; HEART RATE VARIABILITY; HLA TYPING; HUMAN; LEUKOPENIA; MUSCLE CRAMP; NAUSEA AND VOMITING; NURSE; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PHYSICAL EXAMINATION; PHYSICIAN ASSISTANT; PLEURA EFFUSION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SOCIAL WORKER; TEAM NURSING; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84858970983     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.10.004     Document Type: Review

References (34)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17. (Pubitemid 44903745)
2. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251-9.
3. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-70.
4. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358-63.
5. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-40. (Pubitemid 29196596)
6. National Comprehensive Cancer Network. NCCN Guidelines version 1.2012 - chronic myelogenous leukemia. Available at: http://www.nccn.org/professionals/ physician-gls/pdf/cml.pdf. Accessed March 21, 2011.
7. European LeukemiaNet. Recommendations from the European LeukemiaNet for the management of chronic myeloid leukemia (CML). Available at: http://www.leukemia-net.org/content/leukemias/cml/recommendations/. Accessed January 25, 2011.
8. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109:2303-9. (Pubitemid 46425867)
9. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-6. (Pubitemid 350159618)
10. National Cancer Institute. Cancer Topics - PDQ Summaries: Chronic myelogenous leukemia treatment. Available at: http://www.cancer.gov/ cancertopics/pdq/treatment/CML/healthprofessional/allpages. Accessed March 7, 2011.
11. Quintás-Cardama A, Cortes JE, O'Brien S, et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009; 115:2912-21.
12. Fennell ML, Das IP, Clauser S, et al. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr 2010; 2010:72-80.
13. Baccarani M, Dreyling M; ESMO Group Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5):v165-7.
14. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28:2381-8.
15. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood 2011; 117:3733-6.
16. Hussein K, Ketterling RP, Hulshizer RL, et al. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol 2008; 80:318-21. (Pubitemid 351347577)
17. Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 2002; 107:64-75. (Pubitemid 34264170)
18. Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011; 117:1245-52.
19. Branford S, Hughes T, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107:587-99.
20. Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood 2009; 114:3376-81.
21. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37. (Pubitemid 43990609)
22. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9:160-6. (Pubitemid 36109728)
23. Lundan T, Juvonen V, Mueller MC, et al. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica 2008; 93:178-85. (Pubitemid 351397705)
24. Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87:1549-55. (Pubitemid 26056920)
25. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041-51.
26. Gleevec (imatinib mesylate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2010. Available at: http://www.pharma.us. novartis.com/product/pi/pdf/gleevec-tabs.pdf. Accessed March 7, 2011.
27. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2011. Available at: http://www.pharma.us.novartis.com/ product/pi/pdf/tasigna.pdf. Accessed March 7, 2011.
28. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co, 2010. Available at: http://packageinserts.bms.com/pi/ pi-sprycel.pdf. Accessed March 7, 2011.
29. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer 2011; 117:5112-20.
30. Du CZ, Li J, Cai Y, et al. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol 2011; 17:2013-8.
31. Gany F, Ramirez J, Nierodzick ML, et al. Cancer Portal Project: a multidisciplinary approach to cancer care among Hispanic patients. J Oncol Pract 2011; 7:31-8.
32. Guilhot F, Coombs J, Szczudlo T, et al. An ethnographic investigation tracking the experience of chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapies. Blood (ASH Annual Meeting Abstracts) 2010; 116:394.
33. Kim K, Lustria M, Burke D, et al. Predictors of cancer information overload: findings from a national survey. Inf Res 2007; 12 [serial online]. Available at: http://informationr.net/ir/12-4/paper326.html. Accessed September 1, 2011.
34. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006; 103:2794-9.